RxDoctor Payments Data

Katherine Blalock, MD

Family Medicine · Bryan, TXNPI 1083996177

Payments from drug & device makers

$2,475in general payments, 2019–2025

Across 128 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$348
  • Mylan Specialty L.p.$304
  • AstraZeneca$293
  • Avanir Pharmaceuticals, Inc.$245
  • Amgen$236
  • GSK$171
  • plus $879 from 19 others

What the payments were for

  • Food & beverage$2,44799%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,475 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$205,736
Medicare patients
352
Services billed
2,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban323$176,851
OzempicSemaglutide100$126,160
JardianceEmpagliflozin127$117,009
TrulicityDulaglutide59$64,227
MounjaroTirzepatide46$61,239
JanuviaSitagliptin Phosphate31$32,927
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$30,007
XareltoRivaroxaban55$29,270
EntrestoSacubitril/Valsartan53$21,085
RexultiBrexpiprazole12$18,766
Breo ElliptaFluticasone/Vilanterol16$18,009
MyrbetriqMirabegron39$15,894
FarxigaDapagliflozin Propanediol40$13,480
TradjentaLinagliptin30$11,840
SymbicortBudesonide/Formoterol Fumarate27$11,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$348$176,851323 claims
Boehringer IngelheimJardiance, Tradjenta$21$128,849157 claims
Lilly USA, LLCTrulicity, Mounjaro$145$125,466105 claims
GSKTrelegy Ellipta, Breo Ellipta$171$48,01652 claims
Johnson & JohnsonXarelto$123$29,27055 claims
AstraZenecaFarxiga, Symbicort$293$25,13267 claims
NovartisEntresto$17$21,08553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →